In future trials, cerebrospinal fluid levels of α-synuclein oligomers and pro-inflammatory cytokines such as IL-6 and TNF-α may serve as biomarkers of both neurodegeneration and treatment response in PD, potentially reflecting disease-modifying effects through reduced protein aggregation and neuroinflammation. The gene discussed is IL6; the disease is Parkinson disease.